Free Trial

Equities Analysts Set Expectations for SGMO FY2024 Earnings

Sangamo Therapeutics logo with Medical background

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2024 earnings per share estimates for Sangamo Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings per share of ($0.40) for the year, down from their prior estimate of ($0.23). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q4 2024 earnings at $0.07 EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.04) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.07 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.10 EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.63 EPS.

Separately, StockNews.com initiated coverage on Sangamo Therapeutics in a research note on Sunday, July 28th. They issued a "sell" rating for the company.

View Our Latest Stock Analysis on Sangamo Therapeutics

Sangamo Therapeutics Stock Performance

Shares of SGMO stock traded up $0.34 during trading hours on Thursday, reaching $2.81. The company had a trading volume of 15,355,811 shares, compared to its average volume of 6,843,436. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $2.97. The company has a market capitalization of $585.10 million, a P/E ratio of -1.99 and a beta of 1.10. The stock's fifty day simple moving average is $1.08 and its 200 day simple moving average is $0.77.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $11.40 million.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC grew its stake in Sangamo Therapeutics by 4.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock valued at $3,311,000 after purchasing an additional 192,385 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock worth $1,479,000 after buying an additional 1,528,600 shares during the last quarter. Marshall Wace LLP lifted its holdings in Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock worth $207,000 after buying an additional 207,476 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Sangamo Therapeutics during the 1st quarter worth approximately $331,000. Finally, Vontobel Holding Ltd. lifted its holdings in Sangamo Therapeutics by 412.3% during the 3rd quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock worth $259,000 after buying an additional 241,440 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

(Get Free Report)

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Featured Articles

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Should you invest $1,000 in Sangamo Therapeutics right now?

Before you consider Sangamo Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.

While Sangamo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines